Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.60
+0.10 (1.33%)
Oct 8, 2025, 2:09 PM EDT - Market open
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$83,701
Profits / Employee
-$437,348
Market Cap
347.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160 | 58 | 56.86% |
| Dec 31, 2023 | 102 | 28 | 37.84% |
| Dec 31, 2022 | 74 | 26 | 54.17% |
| Dec 31, 2021 | 48 | 22 | 84.62% |
| Dec 31, 2020 | 26 | 10 | 62.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CAPR News
- 5 days ago - Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewsWire
- 8 days ago - Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 - Seeking Alpha
- 9 days ago - Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway - Seeking Alpha
- 13 days ago - Capricor Therapeutics, Inc. - Special Call - Seeking Alpha
- 13 days ago - Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting - GlobeNewsWire
- 25 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - PRNewsWire
- 4 weeks ago - Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel - GlobeNewsWire
- 5 weeks ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewsWire